Corcept Therapeutics, Inc. (NASDAQ: CORT) reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $2.07 million.

For earnings history and earnings-related data on Corcept Therapeutics, Inc. (CORT) click here.

Earnings

Oppenheimer Downgrades Corcept Therapeutics (CORT) to PerformNovember 2, 2012 10:31 AM